SCHEDULE: Deerfield Funds Reduce Stake in ARS Pharmaceuticals to 7.75%

Deerfield Management and its affiliated funds have reduced their beneficial ownership in ARS Pharmaceuticals, Inc. to 7.75% through recent open market sales.

Summary

• Deerfield Management Company, L.P. and James E. Flynn now beneficially own 7,610,217 shares of ARS Pharmaceuticals, Inc. common stock, representing 7.75% of the outstanding shares.
• This ownership is comprised of shares held by Deerfield Private Design Fund III, L.P. (3,805,108 shares or 3.87%) and Deerfield Private Design Fund IV, L.P. (3,805,109 shares or 3.87%).
• Between July 23, 2025, and July 30, 2025, Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. collectively sold 1,023,320 shares of common stock.
• These sales occurred in open market transactions on the Nasdaq Global Market at weighted average prices ranging from $18.01 to $18.36 per share.
• The percentage beneficial ownership is calculated based on 98,213,561 shares of common stock outstanding as of May 12, 2025, as reported by ARS Pharmaceuticals, Inc. in its Quarterly Report on Form 10-Q.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant institutional investor reducing its stake, which can be perceived as a lack of conviction or a strategic exit from a portion of the investment. While not a complete divestment, the reduction of over 1 million shares suggests a less bullish outlook from Deerfield Management.

Negatives

• A significant reduction in beneficial ownership by a major institutional investor, Deerfield Management, from a previously higher stake (implied by Amendment No. 5 and the current 7.75% which is below the 10% threshold for initial 13D filing).
• The sale of 1,023,320 shares over a short period (July 23-30, 2025) could signal a lack of conviction or a strategic exit from a portion of the investment.

Risks

• Potential negative market perception due to a large institutional investor reducing its stake, which could lead to downward pressure on the stock price.
• Reduced institutional support for the company's stock.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding ARS Pharmaceuticals, Inc.'s future performance or strategic direction.

Industry Context

This filing reflects a portfolio adjustment by a significant healthcare-focused investment firm, Deerfield Management, in a biotechnology company. While not indicative of broader industry trends, it highlights the dynamic nature of institutional investment in the biotech sector, where positions are frequently adjusted based on company-specific developments, market conditions, or portfolio rebalancing strategies.

Comparison to Industry Standards

• This filing is a standard Schedule 13D amendment reporting a change in beneficial ownership and does not contain information suitable for comparison to industry-specific operational or financial benchmarks. It details an investment firm's stake reduction, which is a firm-specific portfolio management decision rather than a performance metric comparable across the industry.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on share price due to a large institutional investor reducing its stake.
• Company Management: Could face questions regarding the reasons for the significant investor's stake reduction and its implications for future capital raising or strategic partnerships.

Next Steps

• The filing does not explicitly mention future actions, events, or milestones for ARS Pharmaceuticals, Inc. or the reporting persons beyond the ongoing management of their investment portfolio.

Key Dates

Recommendation

While a significant institutional investor has reduced its stake, the filing itself does not provide new fundamental information about ARS Pharmaceuticals' operations, financial health, or future prospects. The reduction in ownership by Deerfield Management could be due to various reasons, including portfolio rebalancing, profit-taking, or a change in investment thesis. Without additional context on the company's performance or specific reasons for Deerfield's divestment, a 'hold' recommendation is appropriate. Investors should monitor future company announcements and market reactions to assess the long-term implications of this ownership change.

Keywords

ARS Pharmaceuticals, Deerfield Management, Schedule 13D, Beneficial Ownership, Stock Sales, Institutional Investor, Common Stock, Biotechnology, Healthcare Investment